Health · Medical Research · 2 hrs ago
Samsung Bioepis finds Keytruda biosimilar matches original in drug-exposure test
Samsung Bioepis found its Keytruda biosimilar matched the original on a measure of how the drug behaves in the body.
The finding came from a phase 1 clinical trial of the biosimilar, a medicine developed in relation to the original drug.
Pharmacokinetics describes how a drug is absorbed, distributed, processed and removed by the body.
Pharmacokinetic equivalence is an important comparison standard for judging whether two medicines behave similarly in the body.
The result does not, by itself, establish that the biosimilar has the same effectiveness or safety as Keytruda.
The source gives no further trial results or next steps.
Samsung Bioepis said a phase 1 trial found its Keytruda biosimilar pharmacokinetically equivalent to the original medicine.
Pharmacokinetics describes how a drug is absorbed, distributed, metabolised and excreted in the body.
The company discussed the finding during an event in Madrid running from October 23 to 27, local time.
The report was published on October 27, 2026.
- Who
- Samsung Bioepis.
- What
- It reported pharmacokinetic equivalence between its Keytruda biosimilar and the original medicine in a phase 1 trial.
- When
- The report was published on October 27, 2026. The event mentioned ran from October 23 to 27, local time.
- Where
- Madrid, Spain, where the event was held.
- Why
- Not stated
This story does not have two clearly opposing sides.
Samsung Bioepis discussed the trial finding at an event in Madrid.
Chosun Ilbo published its report on the finding.
- Company
- Samsung Bioepis
- Reference medicine
- Keytruda
- Trial phase
- Phase 1
- Finding
- Pharmacokinetic equivalence
- Event location
- Madrid, Spain
- Event dates
- October 23–27, local time